Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Bayer asks U.S. appeals court to reverse $25 million Roundup verdict
Bayer asks U.S. appeals court to reverse $25 million Roundup verdict
(Reuters) - Bayer AG on Monday said it has asked a U.
U.S. government extends deadline to sign up for Obamacare insurance plans
U.S. government extends deadline to sign up for Obamacare insurance plans
(Reuters) - The U.
AZ, Daiichi’s targeted breast cancer therapy on target
AZ, Daiichi’s targeted breast cancer therapy on target
AstraZeneca and Daiichi Sankyo have presented new mid-stage data showing “clinically meaningful” responses in patients with advanced breast cancer taking trastuzumab deruxtecan.
The NHS robots performing major surgery
The NHS robots performing major surgery
2019 has seen a boom in the use of cutting edge robotic technology and there is more to come.
FDA changes course on Sarepta’s once-rejected muscular dystrophy drug
FDA changes course on Sarepta’s once-rejected muscular dystrophy drug
The Food and Drug Administration reversed its decision on a treatment for Duchenne muscular dystrophy from Sarepta Therapeutics (SRPT), approving a previously rejected drug without explaining ...
Senate confirms Stephen Hahn as new FDA chief
Senate confirms Stephen Hahn as new FDA chief
Dr.
FDA underscores that consumers should not use drugs, dietary supplements and devices recalled from Basic Reset and Biogenyx following consent decree for federal violations
FDA underscores that consumers should not use drugs, dietary supplements and devices recalled from Basic Reset and Biogenyx following consent decree for federal violations
The U.
Amneal to buy generic pharmaceuticals provider AvKAR for $340m
Amneal to buy generic pharmaceuticals provider AvKAR for $340m
Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.
Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis
Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis
Dermira has secured fast track designation from the US Food and Drug Administration (FDA) for lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.
Bayer’s $7.6B bid to offload animal health to Elanco draws extra FTC antitrust attention
Bayer’s $7.6B bid to offload animal health to Elanco draws extra FTC antitrust attention
Bayer’s eager to send its animal health unit to Elanco so it can focus its healthcare efforts on pharmaceuticals.
Can Sanofi and Regeneron’s Dupixent steal half of a $21B eczema market? Not so fast: analyst
Can Sanofi and Regeneron’s Dupixent steal half of a $21B eczema market? Not so fast: analyst
Sanofi’s new CEO Paul Hudson turned heads earlier this week with his bold prediction that Dupixent, the company’s eczema drug that’s partnered with Regeneron, would peak at €10 billion ($1...
AstraZeneca-Daiichi drug halts cancer for months in first readout
AstraZeneca-Daiichi drug halts cancer for months in first readout
(Reuters) - An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its firs...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand